A Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00026611|
Recruitment Status : Completed
First Posted : November 13, 2001
Last Update Posted : August 27, 2010
The purpose of this study is to see how many people respond to a smallpox vaccine when a sore forms where the shot was given.
The world was declared free of smallpox in 1980. General routine vaccinations for smallpox were stopped in the U.S. in 1971. In 1976, the recommendation for routine vaccination of healthcare workers was also discontinued. The only people who presently receive this vaccine are people who work with vaccinia virus or monkeypox virus. Because the world was considered free of smallpox infections, this vaccine was no longer produced; there is a limited supply available in the United States.
Because of the limited amount of Dryvax vaccine (vaccinia virus) against smallpox, this study will look at the ability to dilute the vaccine making more doses available in the event of a smallpox outbreak. The study seeks to characterize a strategy of vaccination against smallpox with various doses of Dryvax, followed by revaccination with the same dose, if required, in volunteers 18-32 years of age with a negative history of smallpox vaccination.
|Condition or disease||Intervention/treatment||Phase|
|Smallpox||Biological: Dryvax vaccine||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||A Multicenter, Double-Blind, Randomized Dose-Response Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults|
|Actual Primary Completion Date :||December 2001|
|Actual Study Completion Date :||December 2001|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00026611
|United States, Maryland|
|University of Maryland|
|Baltimore, Maryland, United States|
|United States, Missouri|
|St. Louis University|
|St. Louis, Missouri, United States|
|United States, New York|
|University of Rochester|
|Rochester, New York, United States, 14642|
|United States, Texas|
|Baylor College of Medicine|
|Houston, Texas, United States, 77030|